Detalhe da pesquisa
1.
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.
Cell
; 173(3): 595-610.e11, 2018 04 19.
Artigo
Inglês
| MEDLINE | ID: mdl-29656894
2.
Current and future systemic treatments for renal cell carcinoma.
Semin Cancer Biol
; 23(1): 38-45, 2013 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-22705280
3.
Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
Radiology
; 273(2): 452-61, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-24869795
4.
Parallel evolution of tumour subclones mimics diversity between tumours.
J Pathol
; 230(4): 356-64, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23716380
5.
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas.
J Pathol
; 231(4): 424-32, 2013 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-24122851
6.
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
Eur J Cancer
; 158: 156-168, 2021 Oct 18.
Artigo
Inglês
| MEDLINE | ID: mdl-34678677
7.
Mixed Messages: I. The Consequences of Communicating Negative Statements Within Emotional Support Messages to Cancer Patients.
J Patient Exp
; 7(4): 593-599, 2020 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-33062883
8.
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Nat Med
; 25(8): 1319, 2019 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-31267021
9.
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Nat Med
; 25(6): 936-940, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31171879
10.
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.
Nat Med
; 25(6): 941-946, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-31171878
11.
Individualising treatment choices in a crowded treatment algorithm.
EJC Suppl
; 11(2): 160-8, 2013 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26217125
12.
Treatment of brain metastases in patients with melanoma.
Lancet Oncol
; 13(5): 434-5, 2012 May.
Artigo
Inglês
| MEDLINE | ID: mdl-22456430
13.
A tale of two tumours and a plea for progress.
Lancet Oncol
; 13(2): 124-5, 2012 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-22300855
14.
Endobronchial metastases from renal cell carcinoma: a late manifestation of the disease with an increasing incidence.
BJU Int
; 110(10): 1407-8, 2012 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-22937754
15.
Subsidised access to new melanoma drugs: in need of further innovation?
N Z Med J
; 129(1440): 37-54, 2016 Aug 19.
Artigo
Inglês
| MEDLINE | ID: mdl-27538038
16.
Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
Melanoma Res
; 26(2): 138-44, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26684061
17.
Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution.
Nat Commun
; 6: 6336, 2015 Mar 19.
Artigo
Inglês
| MEDLINE | ID: mdl-25790038
18.
Primary and secondary distant metastatic breast cancer: two sides of the same coin.
Breast
; 23(1): 26-32, 2014 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-24215983
19.
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.
Nat Genet
; 46(3): 225-233, 2014 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-24487277
20.
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.
Genome Biol
; 15(8): 433, 2014 Aug 27.
Artigo
Inglês
| MEDLINE | ID: mdl-25159823